Skip to main content
. 2021 Aug 12;15:100381. doi: 10.1016/j.ynstr.2021.100381

Fig. 6.

Fig. 6

Validation of miR-9-5p target genes. (A,B,C) Relative Luciferase Activity for GSK-3β, REST and SIRT1, long 3′ UTR fragments. Unpaired Student's t-test: *p < 0.05, ***p < 0.001 vs NEG control. n = 3; all experiments were repeated 3 times. (D,E,F) Analysis of GSK-3β, REST and SIRT1 expression in primary hippocampal neurons treated with miR-9-5p mimics or negative control. Unpaired Student's t-test: ***p < 0.001 vs NEG control. n = 9–14. (G,H,I) Analysis of GSK-3β, REST and SIRT1 expression in primary hippocampal neurons treated with corticosterone and ketamine. One-way ANOVA followed by Tukey's post-hoc test: *p < 0.05 vs DMSO; #p < 0.05 vs CORT. n = 6–12. (J,K,L) Analysis of GSK-3β, REST and SIRT1 protein expression in the HPC of CMS rats. One-way ANOVA followed by Tukey's post-hoc test: *p < 0.05, **p < 0.01 vs CNT; #p < 0.05 vs CMS-V; §§p < 0.01 vs CMS-R. n = 4–8.